VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

iwNHL 2015 | Combination studies with venetoclax (ABT-199), BCL-2 inhibitor, for non-Hodgkin lymphoma

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Michael E. Williams, MD, of the University of Virginia School of Medicine, Charlottesville, VA, discusses the clinical development of venetoclax, a selective BCL-2 inhibitor, for the treatment of patients with non-Hodgkin lymphoma. Dr Williams focuses on a phase 1 clinical trial that was designed to determine the optimal dosing scheme for the combination of venetoclax and ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter